Latest News

Learn about our progress, offers and industry news!


A Message From the Company Founders

Welcome new users and valued members to MyRxPal! We have come a long way since our inception back in 2014. Just like our company itself, this website platform is a constant work in progress as we strive to improve our processes, our technologies, and the support services we provide our members. Please take a moment to browse our blog section for any updates and checkout our members only knowledge base for simple questions of our platform . We have tried to be concise and informative and we hope you find our inventory platform beneficial to your pharmacy practice. Stay tuned for more useful features in our growing platform. We measure our success by how successful our members become by operational efficiency. As always, this platform was made with you in mind and we welcome any feedback. Thanks and have a great day!

New Drug Approvals

Source: Drugs.com Headline News

FDA Approves Egaten (triclabendazole) for the Treatment of Fascioliasis, a Neglected Tropical Disease
FDA Approves Darzalex (daratumumab) Split-Dosing Regimen
FDA Approves Cablivi (caplacizumab-yhdp) for Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Adults
FDA Approves Jeuveau (prabotulinumtoxinA-xvfs) for Temporary Improvement in the Appearance of Frown Lines
FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus
FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause
FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine
FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns
FDA Approves Vaxelis Pediatric Hexavalent Combination Vaccine
FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors
FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson’s Disease
FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)